Abstract
Sulfonamide-focused compound libraries have been synthesized in our laboratories for biological evaluation using antitumor phenotypic screens such as cancer cell proliferation assay, flow cytometric cell cycle analysis, and rat aorta tube formation assay. Among thousands of sulfonamide compounds evaluated, E7010 (a microtubule depolymerizing agent), E7070 (a G1 phase cell cycle inhibitor), and E7820 (an antiangiogenesis agent) have progressed to clinical trials, thereby demonstrating some objective responses in cancer patients so far. The sequential discovery of these drug candidates allowed us to carry out a research approach of forward chemical genetics, in which phenotypically bioactive compounds are selected from a large collection of small molecules and then utilized for understanding the functions of their protein partners and relevant biological pathways via target identification. This paper describes our attempt using oligonucleotide microarray and quantitative proteomic analyses not only for identifying drug targets and downstream pathways applicable to biomarkers but also for exploring druggable chemical space in medicinal chemistry research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
